Avalo Therapeutics, Inc.
AVTX
$19.94
-$0.31-1.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -122.78% | -1,155.06% | -27.59% | 151.10% | -11.37% |
| Total Depreciation and Amortization | 103.55% | 175.00% | 145.70% | 69.81% | 6.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 340.90% | 277.02% | -147.39% | -199.96% | -215.64% |
| Change in Net Operating Assets | 181.58% | 176.12% | 143.82% | 74.97% | 49.05% |
| Cash from Operations | -4.90% | -42.08% | -47.78% | -94.97% | -59.90% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -100.00% | -100.00% | -100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -23,055.06% | -23,729.49% | -20,004.49% | -100.00% | 367.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -91.59% | -27.48% | -50.92% | -53.13% | 299.84% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 94.99% | 76.83% | 76.83% | 68.54% | -- |
| Cash from Financing | -91.70% | -24.53% | -43.42% | -43.93% | 602.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -193.27% | -176.36% | -158.59% | -84.02% | 2,303.24% |